Daniel Ontaneda, MD, PhD, Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2024 chair, discussed what attendees can expect at this year's meeting, as well as how the theme of "Breaking Barriers in MS" will be implemented.
New data from SPRINT-MS show that the drug has beneficial effects on slowly evolving lesions in people with multiple sclerosis, perhaps by abrogating chronic active lesions.
The central vein sign is an emerging neuroimaging biomarker for multiple sclerosis that may reduce the need for lumbar puncture to detect oligoclonal bands in CSF, a pilot study shows.